Table 4.
Relative effect of efgartigimod versus ravulizumab in terms of minimum points improvement from baseline at time of best responsea for MG-ADL in people with AChR-Ab+ gMG derived using MAIC
| N | Proportion (95% CI) of patients with minimum points improvement in MG-ADL from baseline at time of best response | |||
|---|---|---|---|---|
| 3 points | 4 points | 5 points | ||
| Adjusted results estimated using reweighted data from the ADAPT study | ||||
| Efgartigimod | 53 | 0.752 (0.633, 0.871)*** | 0.681 (0.553, 0.809)*** | 0.610 (0.476, 0.744)*** |
| Placebo | 55 | 0.374 (0.241, 0.507)*** | 0.253 (0.133, 0.374)*** | 0.145 (0.048, 0.243)** |
| Efgartigimod vs. placebo | 108 | 0.378 (0.200, 0.556)*** | 0.428 (0.252, 0.604)*** | 0.465 (0.296, 0.634)*** |
| Results estimated from the CHAMPION study | ||||
| Ravulizumab | 78 | 0.567 (0.456, 0.678)*** | 0.425 (0.314, 0.536)*** | 0.316 (0.211, 0.421)*** |
| Placebo | 82 | 0.341 (0.236, 0.446)*** | 0.247 (0.151, 0.343)*** | 0.150 (0.071, 0.229)** |
| Ravulizumab vs. placebo | 160 | 0.226 (0.073, 0.379)** | 0.178 (0.031, 0.325)* | 0.166 (0.035, 0.297)* |
| MAIC results anchored on above comparisons with placebo | ||||
| Efgartigimod vs. Ravulizumab | 131 | 0.152 (– 0.085, 0.388) | 0.250 (0.019, 0.480)* | 0.299 (0.085, 0.513)** |
AChR-Ab+ acetylcholine receptor auto-antibody-positive, CI confidence interval, gMG generalized Myasthenia Gravis, MAIC Matching-Adjusted Indirect Comparison, MG-ADL Myasthenia Gravis Activities of Daily Living
*p value < 0.05; **p value < 0.01; ***p value < 0.001
aWeek 4 for efgartigimod and week 26 for ravulizumab